hrp0097p1-499 | GH and IGFs | ESPE2023

Growth characteristics and final height in survivors of childhood medulloblastoma.

Stern Eve , Ben Ami Michal , Caspi Shani , Lurye Michal , Abebe-Campino Gadi , Yalon Michal , Modan-Moses Dalit

Background and aim: Medulloblastoma is a highly malignant childhood brain tumor, requiring treatment with high dose cranio-spinal irradiation and aggressive chemotherapy. Survivors of are at high risk for multiple endocrine deficiencies, including growth retardation and growth hormone (GH) deficiency. Previous studies reported decreased final adult height in survivors of childhood medulloblastoma, with height standard deviation score (SDS) ranging from -1.9 to...

hrp0095fc9.5 | Pituitary, Neuroendocrinology and Puberty | ESPE2022

Gonadal Function, Pubertal Development, and Fertility Outcomes in Male and Female Survivors of Medulloblastoma - a Single Tertiary Centre Experience.

Stern Eve , Ben-Ami Michal , Gruber Noah , Yalon Michal , Abebe-Campino Gadi , Caspi Shani , Lurye Michal , Toren Amos , Modan-Moses Dalit

Background: Endocrine deficiencies, including impairment of the hypothalamic-pituitary-gonadal axis (HPGA), are found in the majority of survivors of medulloblastoma, due to high-dose craniospinal irradiation and gonadotoxic chemotherapy. Data regarding HPGA function in survivors of medulloblastoma is limited to small groups of patients and focusses mainly on female survivors. Furthermore, few studies investigated specific risk factors such as treatment protoc...